Anti-Cancer Pharmaceutical Sunitinib Malate CAS NO.341031-54-7

Anti-Cancer Pharmaceutical Sunitinib Malate CAS NO.341031-54-7

Min.Order / FOB Price:Get Latest Price

10 Gram	FOB Price:USD 1.0000 -2.0000

10 Gram

FOB Price:USD 1.0000 -2.0000

Min.Order :10 Gram
Purity: 99%
Payment Terms : T/T,Other

Keywords

Sunitinib Malate Sunitinib Malate supplier Anti-Cancer

Quick Details

Appearance:yellow solid
Application:Food/Medicine/Industria grade
PackAge:A variety of packing ways for your choice
ProductionCapacity:300|Metric Ton|Month
Storage:Kept in a well-closed, light-resistant,dry and cool place
Transportation:EMS、TNT、DHL、UPS、FEDEX、SF、Wuhan Port、Shanghai Port、Tianjin Port、Guangzhou Port

Superiority:

1,Best Quality:
Our products have exported to Germany, Spain, UK, USA, Australia, Middle East, and so on other countries, and we have got very good feedback from our customers.so you can trust us.
2, Payment method: for example T/T, Westerm Union,other
3, Excellent Service: Best service and after-sales service to all clients.
   1)We will ship the goods within 5days after get your payments.If you want to cancel or change order, please tell me within 24hours after you finish the payment..
   2)We will ship the goods that you order from us by DHL, UPS, TNT and EUB.We will decided to choose which courier depend on different countries.To find the best way to delivery the goods for you.
   3)As usual you can get the goods with in 4-7days.If the goods were lost or not received for other reasons, please contact us immediately.
4,Fast and safe delivery:
Sample Order : As usual you can get the goods within 4-7days. We can send it via HKems, HK Air Post, DHL or other methods.
We have a professional and stable logistics, and we can deliver the package smoothly around 3 to 5 days.
Bulk Order: Shipped via sea or air, it's according to your requirement, delivery time is 7-15days after payment.

We introduce experienced quality product and exceptional JIT service with instant market intelligence in China to benefit our customers and principals. With our high-performance teamwork centers and associated production sites for custom synthesis, we ensure effective professional response and offer extensive applications-related consulting and compliance regulation services.

Details:

Product Name:	Sunitinib Malate
Synonyms:	SUNITINIB MALATE;N-(2-(Diethylamino)ethyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide (2S)-hydroxybutanedioate;N-[2-(Diethylamino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidine)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide(2S)-2-hydroxybutanedioatesalt;Sunitinib Malate(Sutent);Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide (1:1);N-(2-(DiethylaMino)ethyl)-5-((Z)-(5-fluoro-1,2-dih;Butanedioic acid, 2-hydroxy-, (2S)-, coMpd. with N-[2-(diethylaMino)ethyl]-5-[(Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)Methyl]-2,4-diMethyl-1H-pyrrole-3-carboxaMide;(Z)-N-(2-(diethylaMino)ethyl)-5-((5-fluoro-2-oxoindolin-3-ylidene)Methyl)-2,4-diMethyl-1H-pyrrole-3-carboxaMide (S)-2-hydroxysuccinate
CAS:	341031-54-7
MF:	C22H27FN4O2.C4H6O5
MW:	532.566
EINECS:
Product Categories:	APIs;Heterocycles;Intermediates & Fine Chemicals;Pfizer compounds;Pharmaceuticals;Tyrosine Kinase Inhibitors;SU-11248;Inhibitors;Oxetanes
Mol File:	341031-54-7.mol

Anticancer drug	Sunitinib malate is a kind of novel oral multi-targeted anticancer drugs and belongs to multi-targeted tyrosine kinase inhibitor with its trade name being “suntent”. It was successfully developed by Pfizer Company and has dual anti-tumor effect. Moreover, it is the only therapeutic drug which can go beyond the 2-year survival period of advanced kidney cancer and plays a central role in the field of carcinoma and gastrointestinal stromal tumor therapeutic areas. It entered into market in February 2006 in the United States. This drug was the first anti-cancer drug which was approved by the US FDA and can simultaneously treat two diseases. Sunitinib exerts its therapeutic role through preventing the tumor cells from getting the blood and nutrients needed for growth. Clinical trials have showed that the drug can delay the growth rate of gastrointestinal stromal tumors, and can shrink the size of renal cell tumors. Sunitinib malate is the first novel targeted drug being capable of selectively targets drugs for a variety of new tyrosine kinase receptors. It combine two kinds of anti-tumor mechanisms including both stopping the formation of anti-angiogenic which is responsible for supplying blood to tumor and direct attack of tumor cells. It represents the advent of a new round of targeted therapies, being able to attack the tumor directly without the toxicity of the conventional chemotherapy. The indications of Sunitinib malate are as follows: 1, Patients who failed in the treatment with matinib mesylate or of intolerant gastrointestinal stromal tumors (GIST). 2, inoperable advanced renal cell carcinoma (RCC). 3, advanced pancreatic endocrine tumors. The above information is edited by the Chemicalbook of Dai Xiongfeng.
Uses	Anti-cancer drugs
Chemical Properties	Yellow Solid
Usage	Sunitinib Malate (Sutent, SU11248) is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit.
Usage	Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM, and also inhibits c-Kit
Usage	A multi-kinase inhibitor targeting several receptor tyrosine kinases (RTK). Antineoplastic.
Biological Activity	Potent, ATP-competitive VEGFR, PDGFR β and KIT inhibitor (K i values are 2, 9, 17, 8 and 4 nM for VEGFR -1, -2, -3, PDGFR β and KIT respectively). Also inhibits cellular receptor phosphorylation of FLT3, RET and CSF-1R. Exhibits antiangiogenic and antitumor activity in multiple xenograft models.

View All

Visit Store